A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes-Reference-Cited by-同舟云学术

A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes

Published:2023-12 Issue: Volume: Page:
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Fu Edouard L.,Mastrorilli Julianna,Bykov Katsiaryna,Wexler Deborah J.,Cervone Alexander,Lin Kueiyu Joshua,Patorno Elisabetta,Paik Julie M.

Funder

Patient-Centered Outcomes Research Institute

Nederlandse Organisatie voor Wetenschappelijk Onderzoek

National Institutes of Health

National Institute on Aging

U.S. Food and Drug Administration

Publisher

Elsevier BV

Subject

Nephrology

Reference40 articles.

1. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference;Clase;Kidney Int,2020

2. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system;Nilsson;Int J Cardiol,2017

3. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines;Acker;Arch Intern Med,1998

4. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system;Palmer;N Engl J Med,2004

5. Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial;Agarwal;J Am Soc Nephrol,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes;JAMA Internal Medicine;2024-08-12

2. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study;BMJ;2024-06-26

3. A review of the latest real‐world evidence studies in diabetic kidney disease: What have we learned about clinical practice and the clinical effectiveness of interventions?;Diabetes, Obesity and Metabolism;2024-06-20

4. Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists;Kidney International;2024-03